Proclamation April 02, 2026 Doc #2026-06956

Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States

Trade Healthcare Defense Foreign Policy
Share:
Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States
💡

In Simple Terms

This action puts big new taxes on many brand-name drug imports to push more drug making into the United States. It gives lower or no taxes to some firms and countries that agree to make more drugs here or meet other terms, while generic drugs are mostly left out for now.

Summary

President Donald J. Trump issued this proclamation after a Commerce Department investigation found that heavy U.S. reliance on imported patented pharmaceuticals and their ingredients threatens national security. The action imposes a 100 percent tariff on covered patented drugs and pharmaceutical ingredients, while allowing lower or zero tariff rates in certain cases, including for companies with approved plans to move production into the United States, companies with agreements on most-favored-nation pricing and onshoring, and some products covered by trade arrangements or special exemptions. It directs the Secretaries of Commerce and Health and Human Services to negotiate and enforce these agreements, set standards for onshoring plans, monitor compliance, and report back to the President. The proclamation was issued to reduce reliance on foreign-made patented medicines and drug ingredients and strengthen domestic pharmaceutical production tied to national security.

Official Record

Federal Register Published

Signed by the President

April 02, 2026

Published on WhiteHouse.gov

View on WhiteHouse.gov

Published in Federal Register

View on Federal Register View Printed Version (PDF)

April 02, 2026

Document #2026-06956

Analysis & Impact

💡 How This May Affect You

  • Working families and individuals: Brand-name drugs could cost more, but future shortages may lessen if U.S. production expands.
  • Small business owners: Employers, pharmacies, and clinics may face higher medicine costs and supply changes during the transition.
  • Students and recent graduates: Prescription costs may rise now, while domestic manufacturing and research jobs could grow later.
  • Retirees and seniors: People using brand-name medicines may see higher out-of-pocket costs unless exemptions or lower-price deals apply.
  • Different regions: Manufacturing areas may gain jobs; urban hospitals, suburban families, and rural patients could face higher drug costs.

🏢 Key Stakeholders

  • Domestic patented drug manufacturers and API producers benefit from tariff protection and onshoring incentives.
  • Import-dependent branded pharmaceutical companies, hospitals, and patients face higher costs and supply risks.
  • Pharmaceutical manufacturing, API supply chains, trade compliance, and customs brokerage sectors see major disruption.
  • Commerce Department, HHS, USTR, and CBP must negotiate, approve plans, enforce tariffs.
  • PhRMA, domestic manufacturing advocates, patient groups, and free-trade importers will lobby intensely.

📈 What to Expect

  • Short-term (3–12 months):
  • Patented drug import prices rise; some manufacturers seek exemptions, onshoring approval, or MFN deals.
  • Customs compliance burdens increase as firms reclassify products and adjust sourcing.
  • EU, Japan, Korea, Switzerland, and UK intensify negotiations to preserve lower tariff access.
  • Long-term (1–4 years):
  • Some branded drug manufacturing and packaging shifts to U.S. facilities, unevenly across products.
  • Higher costs and supply reshuffling persist for patented medicines lacking exemptions or agreements.
  • Legal challenges, trade disputes, and policy revisions likely reshape tariff scope and enforcement.

📚 Historical Context

  • Echoes Trump’s 2018 Section 232 steel and aluminum tariffs, extending national-security tariffs to pharmaceuticals.
  • Builds on Trump’s 2020 drug-supply-chain orders promoting domestic production, but adds sweeping import duties.
  • Recalls Obama-era concern over drug shortages and biodefense, yet reverses reliance on cooperative resilience measures.
  • Historically notable: first major Section 232 action targeting medicines, not traditional industrial commodities like steel.
  • Distinctive in tying tariff relief to onshoring plans and MFN pricing deals, a novel conditional structure.

Related Actions

Strengthening Actions Taken to Adjust Imports of Aluminum, Steel, and Copper Into the United States

Apr 02, 2026

FR
Proclamation

Strengthening Actions Taken to Adjust Imports of Aluminum, Steel, and Copper Into the United States

Trade Defense Economy Government Reform
Greek Independence Day: A National Day of Celebration of Greek and American Democracy, 2026

Mar 24, 2026

FR
Proclamation

Greek Independence Day: A National Day of Celebration of Greek and American Democracy, 2026

Foreign Policy Civil Rights
National Agriculture Day, 2026

Mar 24, 2026

FR
Proclamation

National Agriculture Day, 2026

Economy Trade Environment Government Reform